Published in Br J Urol on August 01, 1981
Age as prognostic factor in premenopausal breast carcinoma. Lancet (1993) 4.31
Active immunotherapy of L1210 leukaemia applied after the graft of tumour cells. Br J Cancer (1969) 2.96
Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer (1996) 2.95
Anti-colony-stimulating factor-1 antibody staining in primary breast adenocarcinomas correlates with marked inflammatory cell infiltrates and prognosis. J Natl Cancer Inst (1994) 2.58
Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc (2001) 2.55
APC mutations in colorectal tumors with mismatch repair deficiency. Proc Natl Acad Sci U S A (1996) 2.18
Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. Ann Oncol (2007) 2.15
Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med (1990) 2.15
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. Am J Hum Genet (1997) 1.91
Primary chemotherapy for operable breast cancer: incidence and prognostic significance of ipsilateral breast tumor recurrence after breast-conserving surgery. J Clin Oncol (2001) 1.84
Familial invasive breast cancers: worse outcome related to BRCA1 mutations. J Clin Oncol (2000) 1.71
Neoadjuvant versus adjuvant chemotherapy in premenopausal patients with tumours considered too large for breast conserving surgery: preliminary results of a randomised trial: S6. Eur J Cancer (1994) 1.60
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol (1993) 1.60
Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer (2004) 1.58
Linkage of inflammatory bowel disease to human chromosome 6p. Am J Hum Genet (1999) 1.57
No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int J Cancer (1998) 1.52
Outbreak of tuberculosis in a migrants' shelter, Paris, France, 2002. Int J Tuberc Lung Dis (2005) 1.50
Immunologic events and long-term survival after combined heart and kidney transplantation: a 12-year single-center experience. J Heart Lung Transplant (2001) 1.43
Tyrosine phosphorylation of the Fc gamma RIII(CD16): zeta complex in human natural killer cells. Induction by antibody-dependent cytotoxicity but not by natural killing. J Immunol (1991) 1.43
Protracted continuous infusion of 5-fluorouracil in combination with doxorubicin, vincristine, and oral cyclophosphamide in advanced breast cancer. Cancer Invest (1996) 1.42
Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. Int J Radiat Oncol Biol Phys (1992) 1.40
Correlation of pretreatment proliferative activity of breast cancer with the response to cytotoxic chemotherapy. J Natl Cancer Inst (1989) 1.40
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection. Eur J Immunol (1995) 1.39
Contralateral breast cancer: annual incidence and risk parameters. J Clin Oncol (1995) 1.32
Positive margins in laparoscopic partial nephrectomy in 855 cases: a multi-institutional survey from the United States and Europe. J Urol (2007) 1.31
M-CSF (monocyte colony stimulating factor) and M-CSF receptor expression by breast tumour cells: M-CSF mediated recruitment of tumour infiltrating monocytes? J Cell Biochem (1992) 1.31
Targeting HER2 in other tumor types. Ann Oncol (2001) 1.29
In-vitro and in-vivo evidence of dose-dependent decrease of uropathogenic Escherichia coli virulence after consumption of commercial Vaccinium macrocarpon (cranberry) capsules. Clin Microbiol Infect (2008) 1.28
Oral levofloxacin 500 mg once daily in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents (2008) 1.27
Hemispheric disconnection syndrome with a "crossed avoiding" reaction in a case of Marchiafava-Bignami disease. J Neurol Neurosurg Psychiatry (1977) 1.27
Detection of MUC1-expressing mammary carcinoma cells in the peripheral blood of breast cancer patients by real-time polymerase chain reaction. Clin Cancer Res (2000) 1.24
Ewing's family of tumors in adults: multivariate analysis of survival and long-term results of multimodality therapy in 182 patients. J Clin Oncol (1998) 1.23
Attempts at immunotherapy of 100 patients with acute lymphoid leukemia: some factors influencing results. Natl Cancer Inst Monogr (1972) 1.20
[Letter: Toxic polyneuritis in a plastic worker. Possible role of methyl-ethyl-ketone]. Nouv Presse Med (1975) 1.20
Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect (2003) 1.19
Linkage of a QTL contributing to normal variation in bone mineral density to chromosome 11q12-13. J Bone Miner Res (1998) 1.18
Effect of adjuvant chemotherapy on outcome in patients with metastatic breast carcinoma treated with first-line doxorubicin-containing chemotherapy. Cancer (2001) 1.17
Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol (2008) 1.17
Decreased expression of keratinocyte growth factor receptor in a subset of human transitional cell bladder carcinomas. Oncogene (1997) 1.16
Meningeal carcinomatosis in patients with breast carcinoma. Clinical features, prognostic factors, and results of a high-dose intrathecal methotrexate regimen. Cancer (1996) 1.16
Reduction of Escherichia coli adherence to uroepithelial bladder cells after consumption of cranberry juice: a double-blind randomized placebo-controlled cross-over trial. World J Urol (2006) 1.15
Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response. Eur J Cancer (2003) 1.14
Nucleoside diphosphate kinase/NM23 expression in breast cancer: lack of correlation with lymph-node metastasis. Int J Cancer (1992) 1.14
Human papillomavirus genotype as a major determinant of the course of cervical cancer. J Clin Oncol (1998) 1.13
Oncogene amplification correlates with dense lymphocyte infiltration in human breast cancers: a role for hematopoietic growth factor release by tumor cells? J Cell Biochem (1990) 1.12
Prognostic value of persistent node involvement after neoadjuvant chemotherapy in patients with operable breast cancer. Br J Cancer (2000) 1.12
Hepatic resection in metastatic breast cancer: results and prognostic factors. Eur J Surg Oncol (2000) 1.12
Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer (1994) 1.12
Non-Hodgkin's malignant lymphomata of upper digestive and respiratory tract: natural history and results of radiotherapy. Br J Cancer Suppl (1975) 1.11
Prognostic factors in inflammatory breast cancer and therapeutic implications. Eur J Cancer (1994) 1.08
T and B lymphocyte markers on the neoplastic cell of 20 patients with acute and 10 patients with chronic lymphoid leukemia. Biomedicine (1974) 1.07
Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur J Cancer (1995) 1.07
Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology (2001) 1.07
Characterization of AfaE adhesins produced by extraintestinal and intestinal human Escherichia coli isolates: PCR assays for detection of Afa adhesins that do or do not recognize Dr blood group antigens. J Clin Microbiol (2001) 1.06
Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol (1998) 1.05
Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy. Cancer (1996) 1.04
Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme. Oncogene (2012) 1.04
[Hepatic resection for breast cancer metastases: results and prognosis (65 cases)]. Ann Chir (2001) 1.04
Is colony-stimulating factor-1 a key mediator of breast cancer invasion and metastasis? Mol Carcinog (1993) 1.03
Malignant giant-cell tumours of bone. Clinico-pathological types and prognosis: a review of 29 cases. Int Orthop (1998) 1.03
Small intestine protection from radiation by means of a removable adapted prosthesis. Am J Surg (1999) 1.03
Neoadjuvant chemotherapy in operable breast cancer. Eur J Cancer (1991) 1.03
Circulating levels of colony-stimulating factor 1 as a prognostic indicator in 82 patients with epithelial ovarian cancer. Br J Cancer (1994) 1.03
Circulating levels of the macrophage colony stimulating factor CSF-1 in primary and metastatic breast cancer patients. A pilot study. Breast Cancer Res Treat (1996) 1.01
Subdivision of classical varieties of acute leukemia. Correlation with prognosis and cure expectancy. Rev Eur Etud Clin Biol (1972) 1.01
Phase II trial of vinorelbine/doxorubicin as first-line therapy of advanced breast cancer. J Clin Oncol (1994) 1.01
Results of an epidemiological survey using a modified American Urological Association symptom index for benign prostatic hyperplasia in France. J Urol (1994) 1.01
Laparoscopic partial nephrectomy. The European experience. Urol Clin North Am (2000) 1.01
Molecular cloning and characterization of the afa-7 and afa-8 gene clusters encoding afimbrial adhesins in Escherichia coli strains associated with diarrhea or septicemia in calves. Infect Immun (1999) 1.00
[Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)]. Nouv Presse Med (1974) 0.99
Colonization and disinfection of biofilms hosting coliform-colonized carbon fines. Appl Environ Microbiol (1996) 0.99
The relationship between sexual life and urinary condition in the French community. J Clin Epidemiol (1996) 0.99
The inferior hypogastric plexus (pelvic plexus): its importance in neural preservation techniques. Surg Radiol Anat (2003) 0.99
Predictive factors of response to first-line chemotherapy in 1426 women with metastatic breast cancer. Eur J Cancer (2000) 0.98
Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. J Urol (2000) 0.98
Characterization of the AfaD-like family of invasins encoded by pathogenic Escherichia coli associated with intestinal and extra-intestinal infections. FEBS Lett (2000) 0.97
[Extensive idiopathic retroperitoneal fibrosis. Apropos of 16 cases with involvement of the ureter]. Presse Med (1967) 0.97
Predictors of clinical response to interleukin-2--based immunotherapy in melanoma patients: a French multiinstitutional study. J Clin Oncol (1996) 0.97
New insights into p53 function from structural studies. Oncogene (1996) 0.97
Cytokines and soluble cytokine receptor induction after IL-12 administration in cancer patients. Clin Exp Immunol (2000) 0.97
[Therapeutic trials in various hematosarcomas with 4-demethylepipo=dophyllotoxin-beta D thenylidene glucoside (VM 26 or EPT)]. Nouv Presse Med (1974) 0.97
Symptoms and diagnosis of retroperitoneal fibrosis. Analysis of 31 cases. Urol Int (1971) 0.96
No evidence of metabolic disorders 10 to 22 years after Camey type I ileal enterocystoplasty. J Urol (1997) 0.96